Dasatinib, a second-generation tyrosine kinase inhibitor, induces melanogenesis via ERK-CREB-MITF-tyrosinase signaling in normal human melanocytes
- 1 March 2020
- journal article
- research article
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 523 (4) , 1034-1039
Abstract
No abstract availableKeywords
Funding Information
- Basic Science Research Program through the National Research Foundation of Korea
- Ministry of Science, ICT (NRF-2017R1A2B4012542, NRF-2019R1A2C2086127)
- Ministry of Education (2019R1A6C1010003)
This publication has 22 references indexed in Scilit:
- Dasatinib inhibits proinflammatory functions of mature human neutrophilsBlood, 2012
- Dasatinib as a Bone-Modifying Agent: Anabolic and Anti-Resorptive EffectsPLOS ONE, 2012
- Src inhibitors, PP2 and dasatinib, increase retinoic acid-induced association of Lyn and c-Raf (S259) and enhance MAPK-dependent differentiation of myeloid leukemia cellsLeukemia, 2011
- The Tyrosine Kinase Inhibitor Dasatinib Induces a Marked Adipogenic Differentiation of Human Multipotent Mesenchymal Stromal CellsPLOS ONE, 2011
- Nilotinib and MEK Inhibitors Induce Synthetic Lethality through Paradoxical Activation of RAF in Drug-Resistant Chronic Myeloid LeukemiaCancer Cell, 2011
- Malignancies occurring during therapy with tyrosine kinase inhibitors (TKIs) for chronic myeloid leukemia (CML) and other hematologic malignanciesBlood, 2011
- The Src inhibitor dasatinib accelerates the differentiation of human bone marrow-derived mesenchymal stromal cells into osteoblastsBMC Cancer, 2010
- Src family kinases and the MEK/ERK pathway in the regulation of myeloid differentiation and myeloid leukemogenesisAdvances in Enzyme Regulation, 2008
- Melanocyte biology and skin pigmentationNature, 2007
- Dasatinib (BMS-354825) Pharmacokinetics and Pharmacodynamic Biomarkers in Animal Models Predict Optimal Clinical ExposureClinical Cancer Research, 2006